Skip to main content
Top
Published in: International Urology and Nephrology 4/2009

01-12-2009 | Nephrology - Original Paper

Antimicrobial resistance patterns of urinary tract pathogens and rationale for empirical therapy in Turkish children for the years 2000–2006

Authors: Ferhat Catal, Nuket Bavbek, Omer Bayrak, Musemma Karabel, Duran Karabel, Ender Odemis, Ebru Uz

Published in: International Urology and Nephrology | Issue 4/2009

Login to get access

Abstract

Objective

In patients with suspected urinary tract infection (UTI), antibiotic treatment is usually started empirically, before urine culture results are available. Unfortunately, antibiotic resistance has become an increasingly pressing clinical issue in many countries. The objective of this study was to assess the changing susceptibility of urinary pathogens to commonly used antimicrobials in a six-year period to evaluate the options for empirical antibiotic therapy in children with community acquired UTI.

Material and methods

A retrospective analysis of data from all pediatric urine samples processed at Fatih University Medical School microbiology laboratory was undertaken for a period of six years (January 2000–December 2006).

Results

A total of 767 urinary pathogens were isolated from 767 episodes of UTI in 698 patients. The most common causative agent was Escherichia coli (E. coli) followed by Klebsiella spp. and others. In 2000 almost 60% of the E. coli isolates were susceptible to ampicillin (AMP), more than 40% to Co-trimoxazole (SXT), more than 80% to gentamicin (GN), more than 90% to cefuroxime (CXM) and amikacin (AN), and more than 60% to piperacillin (PIP). By 2006 more than 70% were resistant to AMP and more than 50% were resistant to PIP. In 2000 CIP (2.7% resistant isolates) and CXM (3.4% resistant isolates) were the most active agents against Klebsiella spp.; and none of the isolates was found to be resistant to imipenem (IMP). In 2006 GN (2.7% resistant isolates), CIP (3.5% resistant isolates), CXM (2.7% resistant isolates), and AN (8.9% resistant isolates) were the most active agents against these species and still no resistance to IMP was found. For E. Coli the increase in resistance to AMP, CTX, IMP, and PIP was statistically significant (P < 0.05). For Klebsiella spp. the increase in resistance to AMP and CXM was statistically significant (P < 0.05).

Conclusions

Empirical antibiotic selection should be based on knowledge of the local prevalence of bacterial organisms and antibiotic sensitivities, because resistance patterns may vary in different regions.
Literature
1.
go back to reference Elder JS (2000) Urologic disorders in infants and children. In: Behrman RE, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 16th edn. WB Saunders, Philadelphia, pp 1621–1625 Elder JS (2000) Urologic disorders in infants and children. In: Behrman RE, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 16th edn. WB Saunders, Philadelphia, pp 1621–1625
3.
go back to reference Allen UD, MacDonald N et al (1999) Risk factors for resistance to ‘first-line’ antimicrobials among urinary tract isolates of Escherichia coli in children. CMAJ 160:1436–1440PubMed Allen UD, MacDonald N et al (1999) Risk factors for resistance to ‘first-line’ antimicrobials among urinary tract isolates of Escherichia coli in children. CMAJ 160:1436–1440PubMed
6.
go back to reference National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Approved Standard. M100-S12. NCCLS, Wayne, PA National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Approved Standard. M100-S12. NCCLS, Wayne, PA
8.
go back to reference Barrett SP, Savage MA, Rebec MP, Guyot A, Andrews N, Shrimpton SB (1999) Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. J Antimicrob Chemother 44:359–365. doi:10.1093/jac/44.3.359 CrossRefPubMed Barrett SP, Savage MA, Rebec MP, Guyot A, Andrews N, Shrimpton SB (1999) Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. J Antimicrob Chemother 44:359–365. doi:10.​1093/​jac/​44.​3.​359 CrossRefPubMed
9.
go back to reference Beunders AJ (1994) Development of antibacterial resistance. The Dutch experience. J Antimicrob Chemother 33:17–22PubMed Beunders AJ (1994) Development of antibacterial resistance. The Dutch experience. J Antimicrob Chemother 33:17–22PubMed
12.
go back to reference Weber G, Riesenberg K et al (1997) Changing trends in frequency and antimicrobial resistance of urinary pathogens in outpatient clinics and a hospital in Southern Israel, 1991–1995. Eur J Clin Microbiol Infect Dis 16:834–835. doi:10.1007/BF01700414 CrossRefPubMed Weber G, Riesenberg K et al (1997) Changing trends in frequency and antimicrobial resistance of urinary pathogens in outpatient clinics and a hospital in Southern Israel, 1991–1995. Eur J Clin Microbiol Infect Dis 16:834–835. doi:10.​1007/​BF01700414 CrossRefPubMed
15.
go back to reference Bronzwaer SL, Cars O, and participants in the European Antimicrobial Surveillance System et al (2002) A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 8:278–282CrossRefPubMed Bronzwaer SL, Cars O, and participants in the European Antimicrobial Surveillance System et al (2002) A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 8:278–282CrossRefPubMed
18.
go back to reference Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH (2000) Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 21:455–458. doi:10.1086/501787 CrossRefPubMed Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH (2000) Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 21:455–458. doi:10.​1086/​501787 CrossRefPubMed
19.
go back to reference Toltzis P, Dul M et al (2003) Cefepime use in pediatric intensive care unit reduces colonization with resistant bacilli. Pediatr Infect Dis J 22:109–114PubMed Toltzis P, Dul M et al (2003) Cefepime use in pediatric intensive care unit reduces colonization with resistant bacilli. Pediatr Infect Dis J 22:109–114PubMed
21.
go back to reference Goldmann DA, Weinstein RA et al (1996) Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. Workshop to Prevent, Control the Emergence, Spread of Antimicrobial-Resistant Microorganisms in Hospitals. JAMA 275:234–240. doi:10.1001/jama.275.3.234 CrossRefPubMed Goldmann DA, Weinstein RA et al (1996) Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. Workshop to Prevent, Control the Emergence, Spread of Antimicrobial-Resistant Microorganisms in Hospitals. JAMA 275:234–240. doi:10.​1001/​jama.​275.​3.​234 CrossRefPubMed
Metadata
Title
Antimicrobial resistance patterns of urinary tract pathogens and rationale for empirical therapy in Turkish children for the years 2000–2006
Authors
Ferhat Catal
Nuket Bavbek
Omer Bayrak
Musemma Karabel
Duran Karabel
Ender Odemis
Ebru Uz
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2009
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9445-5

Other articles of this Issue 4/2009

International Urology and Nephrology 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine